Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Effect of Dapagliflozin on 24-hour Blood Glucose in 92 Type 2 Diabetes Patients Inadequately Controlled With Either Metformin Or Insulin
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes mellitus (T2DM)
Treated with either stable dose of metformin alone \> or = to 1500mg/day or stable dose of insulin \> or = to 30 units/day and up to 2 OAD medications for at least 8 weeks
Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening
Body mass index (BMI) \< or = to 45 kg/m2
You may not be if
For patients who enter the study taking a stable dose of metformin, history of taking OAD medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening
For patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to screening.
Use of sulfonylureas during the 8 weeks prior to screening
Prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (SGLT-2) inhibitor
Ingestion of any medication know to affect glucose metabolism for \>7 consecutive days during the 3 months prior to screening
Ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
